Coeptis Therapeutics Holdings, Inc.
NASDAQ: COEP0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David Mehalick
- Employees
- 6
- Headquarters
- Wexford, United States
- IPO year
- 2020
- Market cap
- $49.1M
- Website
- https://coeptistx.com
Loading COEP…
Loading profile data…Frequently asked questions about COEP
What does Coeptis Therapeutics Holdings, Inc. (COEP) do?
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified n...
Where does COEP trade?
Coeptis Therapeutics Holdings, Inc. (COEP) trades on the NASDAQ.
What sector is COEP in?
Coeptis Therapeutics Holdings, Inc. (COEP) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Coeptis Therapeutics Holdings, Inc.?
David Mehalick is the chief executive officer of Coeptis Therapeutics Holdings, Inc. (COEP).
Where is Coeptis Therapeutics Holdings, Inc. headquartered?
Coeptis Therapeutics Holdings, Inc. is headquartered in United States.
Does COEP pay a dividend?
Coeptis Therapeutics Holdings, Inc. (COEP) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did COEP go public?
Coeptis Therapeutics Holdings, Inc. (COEP) completed its initial public offering in 2020.